c-MYC is a well-validated oncogene with broad anti-cancer potential, as c-MYC expression is dysregulated in more than 70% of cancers and a key regulator in nearly every aspect of the oncogenic ...

Besides, c-Myc is also known as a factor necessary for the initial induction of iPS cells. In the future this inhibition can be expected to be applied as a technology that can also be used to ...

A. 3HA-c-Myc was co-expressed with FLAG-USP17 (WT or the catalytically inactive mutant (C89S)) in COS7 cells. After 24 h, cell lysates were immunoblotted with the indicated antibodies.

The mechanism by which cells mature and die is malleable, but so far it has not been possible to reverse this natural process ...

c-Myc plays a regular part in this protein production process—and cellular growth in general—and humans could not live without it. Occasionally, this process is disrupted.

Targeting MYC is therefore highly desirable. Still, finding c-MYC inhibitors for therapeutic use has been problematic and MYC itself has long been viewed as "undruggable".

Conclusions: A high c-Myc expression in naïve CC might discriminate patients with a lower TTP and a worse prognosis. Moreover, the significant c-Myc pathway upregulation, unrelated to miRNAs ...